Form 8-K - Current report:
SEC Accession No. 0001193125-24-272464
Filing Date
2024-12-06
Accepted
2024-12-06 16:15:32
Documents
15
Period of Report
2024-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d899818d8k.htm   iXBRL 8-K 32538
2 EX-4.1 d899818dex41.htm EX-4.1 11618
  Complete submission text file 0001193125-24-272464.txt   207379

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20241203.xsd EX-101.SCH 3884
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20241203_def.xml EX-101.DEF 13699
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20241203_lab.xml EX-101.LAB 22683
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20241203_pre.xml EX-101.PRE 14667
18 EXTRACTED XBRL INSTANCE DOCUMENT d899818d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 241532480
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)